Clinical Trials on Alzheimer's Type Dementia in Australia

Total 3165 results

Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Completed

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, France, Spain, Ireland, Australia, Puerto Rico, United Kingdom
Athira Pharma
National Institute on Aging (NIA)

Completed

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease (ACT-AD)

Alzheimer Disease | Dementia of Alzheimer Type

United States, Australia
Medical University of Graz
Joanneum Research Forschungsgesellschaft mbH; Sozialverein Deutschlandsberg... and other collaborators

Unknown

Playful Multimodal Intervention, Monitoring and Decision Support for Activation of People With Alzheimer's Dementia (M-AAL)

Alzheimer Disease

Austria
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, France, Ireland, Mexico, Netherlands, Puerto Rico, Spain, United Kingdom, Brazil, Japan, Germany
Actinogen Medical

Recruiting

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease (XanaMIA)

Alzheimer Disease | Dementia, Mild | Dementia Moderate

Australia
University of South Australia
Flinders University

Recruiting

Small Steps Towards Improving Activity and Sleep Habits to Decrease the Risk of Dementia

Dementia | Alzheimer Disease

Australia
SciNeuro

Completed

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

Neurodegenerative Diseases | Alzheimer's Disease

Australia
Cerecin

Terminated

Tricaprilin Liquid Formulation PK Study

Alzheimer Disease

Australia
Sanofi

Completed

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

Dementia Alzheimer's Type

Australia, Italy, France, Portugal, United States, Canada, Germany, Poland, Spain
Washington University School of Medicine
National Institute on Aging (NIA); Alzheimer's Association; Eisai Inc.; Accelerating...

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, Netherlands, Puerto Rico, Spain, United Kingdom, France, Ireland, Mexico, Brazil, Japan, Germany
Lyndra Inc.

Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults

Healthy | Alzheimer Disease | Gastric Retention

Australia
Inventage Lab., Inc.

Recruiting

A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.

Alzheimer Disease

Australia
Actinogen Medical
Avance Clinical

Completed

A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers (XanaMIA-DR)

Mild Cognitive Impairment | Alzheimer's Disease

Australia
Seelos Therapeutics, Inc.

Withdrawn

SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease ([STRIVE-AD])

Alzheimer's Disease

Australia
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE)

Alzheimers Disease

United States, United Kingdom, Korea, Republic of, Poland, Canada, Australia, Argentina, Spain, Sweden, Italy
Neuroscience Trials Australia
The Florey Institute of Neuroscience and Mental Health

Active, not recruiting

Deferiprone to Delay Dementia (The 3D Study)

Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Mild Alzheimer's Disease

Australia
Anavex Life Sciences Corp.

Completed

An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Australia
Anavex Life Sciences Corp.

Completed

Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease (ANAVEX)

Alzheimer's Disease

Australia
Hoffmann-La Roche

Recruiting

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimers Disease

Korea, Republic of, United States, Canada, Poland, Spain, Australia, Japan, Chile, United Kingdom
Asceneuron Pty Ltd.
Neuroscience Trials Australia; Asceneuron S.A.

Terminated

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

Alzheimer Disease

Australia
Cerecin

Completed

Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production

Alzheimer Disease

Australia
Cerecin

Completed

AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions

Alzheimer Disease

Australia
Cerecin

Completed

Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production

Alzheimer Disease

Australia
VTBIO Co. LTD
BHT Lifescience Austrailia Pty Ltd.

Unknown

A Safety and Tolerability Study of GB301

Alzheimer Disease

Australia
Washington University School of Medicine
Hoffmann-La Roche; Genentech, Inc.; National Institute on Aging (NIA); Alzheimer...

Suspended

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, France, Spain, Ireland, Argentina, Australia, Colombia, Germany, Mexico, Netherlands, Puerto Rico, United Kingdom
Debiopharm International SA

Completed

Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease (BRAINz)

Moderate Alzheimer's Disease

Australia, Canada, United Kingdom
Affiris AG

Completed

AD01 Follow up Extension Visit

Alzheimer´s Disease

Austria
Atridia Pty Ltd.

Completed

A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects

Alzheimer Disease

Australia
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers

Alzheimer's Disease

Australia
Atridia Pty Ltd.

Not yet recruiting

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease (AD)

Australia
GlaxoSmithKline

Completed

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

Alzheimer's Disease

Australia, Sweden, Norway
Affiris AG

Terminated

Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease

Alzheimer´s Disease

Austria
Avid Radiopharmaceuticals

Completed

Florbetapir Calibration to the Centiloid Scale

Alzheimer's Disease

United States, Australia
Cognition Therapeutics

Completed

Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Australia
Sanofi

Completed

Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Alzheimer Disease

United States, France, Netherlands, Spain, Singapore, Taiwan, Hong Kong, South Africa, Australia, Italy
Pfizer

Completed

A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Canada, United Kingdom, Australia, Sweden
University of Manitoba

Unknown

Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease

Alzheimer's Disease

Canada, Australia
Inmune Bio, Inc.
Alzheimer's Association

Completed

A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's

Alzheimer Disease

Australia
Janssen-Cilag Pty Ltd

Completed

An Observational Study of the Safety and Effectiveness of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-month Period

Dementia | Alzheimer Disease | Galantamine

Australia
Novartis Pharmaceuticals
National Institute on Aging (NIA); Amgen; Banner Alzheimer's Institute

Terminated

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1)

Alzheimers Disease

United States, Belgium, United Kingdom, Germany, Australia, Canada, Spain, Finland, Switzerland, Netherlands
Inmune Bio, Inc.

Recruiting

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | Tauopathies

Australia, Canada
Bayside Health

Completed

Impact of a Memory Group for Older Adults Reporting Memory Difficulties

Mild Cognitive Impairment | Alzheimer's Disease

Australia
reMYND
NeuroScios GmbH

Completed

A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127

Alzheimer Disease

Austria
Affiris AG

Completed

Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Austria
Affiris AG

Completed

Long-term Safety and Tolerability of AFFITOPE AD01

Alzheimer's Disease

Austria
Affiris AG

Completed

Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02

Alzheimer's Disease

Austria
Affiris AG

Completed

Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Austria
Storz Medical AG
Medical University of Vienna

Completed

Brain Stimulation for Neurological Patients

Alzheimer Disease

Austria
Ever Neuro Pharma GmbH

Withdrawn

Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT) (DAT)

Alzheimer Disease

Austria
Affiris AG

Completed

Safety and Tolerability of AFFITOPE AD03 (MimoVax)

Alzheimer's Disease

Austria

Clinical Trials on Alzheimer's Type Dementia in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations